MCSim-related pages
GNU MCSim page on Wikipedia
Journal of Statistical Software
Duke University: Institute of Statistics and Decision Sciences
A real conversation supported by an MCSim simulation model
Scientific works acknowledging the use of MCSim
  1. Tebby C., van der Voet H., de Sousa G., Rorije E., Kumar V., de Boer W., Kruisselbrink J.W., Bois F., Faniband M., Moretto A., Brochot C., 2020, A generic PBTK model implemented in the MCRA platform: predictive performance and uses in risk assessment of chemicals, Food and Chemical Toxicology, 142:111440, doi:10.1016/j.fct.2020.111440.
  2. Simeon S., Brotzmann K., Fisher C., Gardner I., Silvester S., Maclennan R., Walker P., Braunbeck T., Bois F., 2020, PBPK modeling of the zebrafish embryo for developmental toxicity assessment, Reproductive Toxicology, 93:219-229, doi:10.1016/j.reprotox.2020.02.010.
  3. Codaccioni M., Bois F., Brochot C., 2019, Placental transfer of xenobiotics in pregnancy physiologically-based pharmacokinetic models: structure and data, Computational Toxicology, 12:100111, doi:10.1016/j.comtox.2019.100111.
  4. Brochot C., Casas M., Manzano-Salgado C., Zeman F.A., Schettgen T., Vrijheid M., Bois F., 2019, Prediction of maternal and foetal exposures to perfluoroalkyl compounds in a Spanish birth cohort using toxicokinetic modelling, Toxicology and Applied Pharmacology, 379:114640, doi:10.1016/j.taap.2019.114640.
  5. Tsiros P., Bois F., Dokoumetzidis A., Sarimveis H., 2019, Population pharmacokinetic reanalysis of a diazepam PBPK Model - A Comparison of Stan and GNU MCSim, Journal of Pharmacokinetics and Pharmacodynamics, 46:173-192, doi: 10.1007/s10928-019-09630-x.
  6. Zgheib E., Gao W., Limonciel A., Aladjov H., Yang H., Tebby C., Gayraud G., Jennings P., Sachana M., Beltman J.B., Bois F., 2019, Application of three approaches for quantitative AOP development to renal toxicity, Computational Toxicology, 11:1-13, doi:10.1016/j.comtox.2019.02.001.
  7. Battistoni M., Di Renzo F., Menegola E., Bois F., 2019, Quantitative AOP-based teratogenicity prediction for mixtures of azole fungicides, Computational Toxicology, 11:72-81, doi:10.1016/j.comtox.2019.03.004.
  8. Grech A., Tebby C., Brochot C., Bois F., Bado-Nilles A., Dorne J.-L., Quignot N., Beaudouin R., 2019. Generic physiologically-based toxicokinetic modelling for fish: Integration of environmental factors and species variability. Science of The Total Environment, 651:516-531, doi:10.1016/j.scitotenv.2018.09.163.
  9. Hsieh N.-H., Reisfeld B., Bois F., Chiu W., 2018, Applying a global sensitivity analysis workflow to improve the computational efficiencies in physiologically-based pharmacokinetic modeling, Frontiers in Pharmacology, 9:588, doi:10.3389/fphar.2018.00588.
  10. Berggren E., White A., Ouedraogo G., Paini A., Richarz A.-N., Bois F., Exner T., Leite S., van Grunsven L.A., Worth A., Mahony C., 2017, Ab initio chemical safety assessment: a workflow based on exposure considerations and non-animal methods, Computational Toxicology, 4:31-44, doi:10.1016/j.comtox.2017.10.001.
  11. Bois F., Diaz Ochoa J.G. Gajewska M., Kovarich S., Mauch K., Paini A., Péry A., Sala Benito J.V., Teng S., Worth A., 2017, Multiscale modelling approaches for assessing cosmetic ingredients safety, Toxicology, 392:130-139, doi:10.1016/j.tox.2016.05.026.
  12. Bois F., Golbamaki-Bakhtyari N., Kovarich S., Tebby C., Gabb H.A., Lemazurier E., 2017, A high-throughput analysis of ovarian cycle disruption by mixtures of aromatase inhibitors, Environmental Health Perspectives, 077012-1, doi:10.1289/EHP742.
  13. Grech A., Brochot C., Dorne J.-L., Quignot N., Bois F., Beaudouin R., 2017, Toxicokinetic models and related tools in environmental risk assessment of chemicals, Science of the Total Environment, 578:1-15, doi:10.1016/j.scitotenv.2016.10.146.
  14. Nicoulaud-Gouin V., Giacalone M., Attard J.-C., Martin-Garin A., Garcia-Sanchez L., Bois F., 2016, Parameter identification and comparison of radionuclides transfer models using a Bayesian approach, Journal of Environmental Radioactivity, 162-163: 328-339, doi:10.1016/j.jenvrad.2016.06.008.
  15. Bois F., Brochot C., 2016, Modeling pharmacokinetics, in In Silico Methods for Predicting Drug Toxicity, Benfenati E. Ed., Methods in Molecular Biology Series, 1425:37-62, Humana Press, New-York, doi:10.1007/978-1-4939-3609-0_3.
  16. Leclerc E., Hamon J. Bois F., 2016, Investigation of ifosfamide and chloroacetaldehyde renal toxicity through integration of in vitro liver-kidney microfluidic data and pharmacokinetic-system biology models, Journal of Applied Toxicology, 36:330-339.
  17. Hamon J., Renner M., Jamei M., Lukas A., Kopp-Schneider A., Bois F, 2015, Quantitative in vitro to in vivo extrapolation of tissues toxicity, Toxicology in Vitro, 30:203-216.
  18. Crean D., Bellwon P., Aschauer L., Limonciel A., Moenks K., Hewitt P., Schmidt T., Herrgen K., Dekant W., Lukas A., Bois F., Wilmes A., Jennings P., Leonard M.O., 2015, Adefovir accumulates and its toxicity enhanced in renal epithelial cells exposed to hypoxic stress, Toxicology in Vitro, 30:128-137.
  19. Pomponio G., Savary C., Parmentier C., Bois F., Guillouzo A., Romanelli L., Richert L., Di Consiglio E., Testai E., 2015, In vitro kinetics of amiodarone and its major metabolite in two human-derived cell models after acute and repeated exposure, Toxicology in Vitro, 30:36-51.
  20. Bellwon P., Truisi G.L., Bois F., Wilmes A., Schmidt T., Savary C.C., Parmentier C., Hewitt P., Schmal O., Josse R., Richert L., Mueller S.O., Jennings P., Testai E., Dekant W.,2015, Kinetics and dynamics of cyclosporine A in three hepatic cell culture systems, Toxicology in Vitro, 30:62-78.
  21. Wilmes A., Bielow C., Ranninger C., Bellwon P., Aschauer L., Limonciel A., Chassaigne H., Kristl T., Aiche S., Huber C.G., Guillou C., Hewitt P., O Leonard M.O., Dekant W., Bois F., Jennings P., 2015, Mechanism of cisplatin proximal tubule toxicity revealed by integrating, transcriptomics, proteomics, metabolomics and biokinetics, Toxicology in Vitro, 30:117-127. doi: 10.1016/j.tiv.2014.10.006.
  22. Truisi G., Di Consiglio E., Parmentier C., Savary C., Pomponio G., Bois F., Lauer B., Josse R., Hewitt P., Mueller S., Richert L., Guillouzo A., Testai E., 2015, Understanding the biokinetics of ibuprofen after single and repeated treatments in rat and human in vitro liver cell systems, Toxicology Letters, 233:172-186, doi: 10.1016/j.toxlet.2015.01.006.
  23. Bricks T., Hamon J., Fleury M.J., Jellali R., Merlier F., Herpe Y.E., Seyer A., Regimbeau J-M., Bois F., Leclerc E., 2015, investigation of omeprazole and phenacetin first-pass metabolism in humans using a microscale bioreactor and pharmacokinetic models, Biopharmaceutics and Drug Disposition, 36:275-293, doi:10.1002/bdd.1940.
  24. Leclerc E., Hamon J., Claude I., Jellali R., Naudot M., Bois F., 2015, Investigation of acetaminophen toxicity in HepG2/C3a microscale cultures using a system biology model of glutathione depletion, Cell Biology and Toxicology, 31:173-185, doi:10.1007/s10565-015-9302-0.
  25. Prot J.M., Maciel L., Bricks T., Merlier F., Cotton J., Paullier P., Bois F., Leclerc E., 2014, First pass intestinal and liver metabolism of paracetamol in a microfluidic platform coupled with a mathematical modeling as a means of evaluating ADME processes in humans, Biotechnology and Bioengineering, 111:2027-2040.
  26. Hamon J., Jennings P., Bois F., 2014, Systems biology modeling of omics data: effect of cyclosporine a on the Nrf2 pathway in human renal cells. BMC Systems Biology 8:76, doi: 10.1186/1752-0509-8-76.
  27. Leclerc E., Hamon J., Legendre A., Bois F., 2014, Integration of pharmacokinetic and NRF2 system biology models to describe reactive oxygen species production and subsequent glutathione depletion in liver microfluidic biochips after flutamide exposure, Toxicology in Vitro, 28:1230-1241.
  28. Quignot N., Hamon J., Bois F., 2014, Extrapolating in vitro results to predict human toxicity, in In Vitro Toxicology Systems, Bal-Price A., Jennings P., Eds, Methods in Pharmacology and Toxicology series, Springer Science, New York, USA, p. 531-550.
  29. Baudoin R., Legendre A., Jacques S., Cotton J., Bois F., Leclerc E., 2014, Evaluation of a liver microfluidic biochip to predict in vivo clearances of seven drugs in rats, Journal of Pharmaceutical Sciences 103:706-718.
  30. Geenen S., Yates J., Kenna J.G., Bois F., Wilson I.D., Westerhoff H.V., 2013, Multiscale modelling approach combining a kinetic model of glutathione metabolism with PBPK models of paracetamol and glutathione-depleting biomarkers ophthalmic acid and 5- oxoproline in humans and rats, Integrative Biology. 5:877-888.
  31. Wilmes A., Limonciel A., Aschauer L., Moenks K., Bielow C., Leonard M.O., Hamon J., Carpi D., Ruzek S., Handler A., Schmal O., Herrgen K., Bellwon P., Burek C., Truisi G.L., Hewitt P., Di Consiglio E., Testai E., Blaauboer B.J., Guillou C., Huber C.G., Lukas A., Pfaller W., Mueller S.O., Bois F., Dekant W., Jennings P., 2013, Integrated omic profiling reveals novel insights of cyclosporine A induced cellular stress, Journal of Proteomics, 79:180-194, doi: 10.1016/j.jprot.2012.11.022.
  32. Quignot N., Bois F., 2013, A computational model to predict rat ovarian steroid secretion from in vitro experiments with endocrine disruptors, PLoS ONE, 8(1):e53891, doi:10.1371/journal.pone.0053891.
  33. Bois F., 2013, Bayesian inference, in Computational Toxicology vol. II, Reisfeld B., Mayeno A.N. Eds., Methods in Molecular Biology Series, 930:597-636, Humana Press, New-York, doi: 10.1007/978-1-62703-059-5_25.
  34. Dorne J.L., Amzal P., Bois F., Crepet A., Tressou J., Verger P., 2012, Population effects and variability, in Computational Toxicology vol. I, Reisfeld B., Mayeno A.N. Eds., Methods in Molecular Biology Series, 929:521-581, Humana Press, New-York, doi: 10.1007/978-1-62703-050-2_20.
  35. Bois F., Jamei M., 2012, Population-based pharmacokinetic modeling and simulation, in Encyclopedia of Drug Metabolism and Interactions, Lyubimov A.V., Ed., John Wiley & sons, Hoboken, vol. XI, p. 1-27, doi: 10.1002/9780470921920.edm135.
  36. Prot J.M., Bunescu A., Elena-Hermann B., Aninat C., Snouber L., Griscom L., Razan F. , Bois F., et al., 2012, Predictive toxicology using systemic biology and liver microfluidic approaches : application to acetaminophen injury, Toxicology and Applied Pharmacology, 259:270-280.
  37. Cheng S., Bois F., 2011, A mechanistic modeling framework for predicting metabolic interactions in complex mixtures, Environmental Health Perspectives, 119:1712-1718.
  38. Ngo L., Ryan L.M., Mezzetti M., Bois F., Smith T.J., 2011, Estimating metabolic rate for butadiene at steady state using a Bayesian physiologically-based pharmacokinetic model, Journal of Environmental and Ecological Statistics, 18:131-146, doi: 10.1007/s10651-009-0124-1.
  39. Bois F., Jamei M., Clewell H.J., 2010, PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals, Toxicology, 278:256-267.
  40. Bois F., 2010, Physiologically-based modelling and prediction of drug interactions, Basic and Clinical Pharmacology and Toxicology, 106 :154-161, doi: 10.1111/j.1742-7843.2009.00488.x.
  41. Bois F., Habka D., Brochot C., 2010, An integrated modelling approach for in vitro to in vivo extrapolations, ALTEX - Alternatives to Animal Experimentations, 27:103-108.
  42. Martin A., Bois F., Pierre F., Wild P., 2010, Occupational exposure to cobalt : a population toxicokinetic modelling approach validated by field results challenges the Biological Exposure Index for urinary cobalt, Journal of Occupational and Environmental Hygiene, 7:54-62.
  43. Bois F., 2009, [Physiological modeling of metabolic interactions], Environnement, Risques et Santé, 8:413-424.
  44. Bois F., 2009, GNU MCSim: Bayesian statistical inference for SBML-coded systems biology models, Bioinformatics, 25:1453-1454, doi: 10.1093/bioinformatics/btp162.
  45. Péry A., Bois F., 2009, Adaptation of PBPK model equations to study compound concentration stochasticity in cells and cancer risk assessment, Risk Analysis, 29:1182-1191, doi: 10.1111/j.1539-6924.2009.01242.x.
  46. Péry A., Brochot C., Hoet P., Nemmar A., Bois F., 2009, Development of a physiologically-based kinetic model for 99m-Technetium labelled carbon nanoparticles inhaled by humans, Inhalation Toxicology, 21:1099-1107, doi: 10.3109/08958370902748542.
  47. Smith T., Bois F., Lin Y.-S., Brochot C., Micallef S., Kim D., Kelsey K.T., 2008, Quantifying heterogeneity in exposure-risk relationships using exhaled breath biomarkers for 1,3-butadiene exposures, Journal of Breath Research, 2:037018 (10 p.)
  48. Loizou G., Spendiff M., Barton H.A., Bessems J., Bois F., Bouvier d†¢Yvoire M., Buist H., Clewell H.J.III, Meek B., Gundert-Remy U., Goerlitz G., Schmitt W., 2008, Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps, Regulatory Toxicology and Pharmacology, 50:400-411.
  49. Bouvier d†¢Yvoire M., Prieto P., Blaauboer B.J., Bois F., Boobis A., Brochot C., Coecke S., Freidig A., Gundert-Remy U., Hartung T., Jacobs M. N., Lavé T., Leahy D.E., Lennernäs H., Loizou G.D., Meek B., Pease C., Rowland M., Spendiff M., Yang J., Zeilmaker M., 2007, Physiologically-based kinetic modelling (PBK modelling): meeting the 3Rs agenda - The report and recommendations of ECVAM Workshop 63a, Alternatives to Laboratory Animals, 35:661•¡¹671.
  50. Barton H.A., Chiu W.A., Setzer W., Andersen M.E., Bailer A.J., Bois F., DeWoskin R.S., Hays S., Johanson G., Jones N., Loizou G., MacPhail R.C., Portier C.J., Spendiff M., Tan Y.-M., 2007, Characterizing uncertainty and variability in physiologically-based pharmacokinetic (PBPK) models: state of the science and needs for research and implementation, Toxicological Sciences, 99: 395-402.
  51. Chiu W.A., Bois F., 2007, An approximate method for population toxicokinetic analysis with aggregated data, Journal of Agricultural, Biological, and Environmental Statistics, 12:346-363.
  52. Brochot C., Smith T.J., Bois F., 2007, Development of a physiologically based toxicokinetic model for butadiene and four major metabolites in humans: Global sensitivity analysis for experimental design issues, Chemico-Biological Interactions, 167:168-183.
  53. Chiu W.A., Micallef S., Monster A.C., Bois F., 2007, Toxicokinetics of inhaled trichloroethylene and tetrachloroethylene in humans at 1 ppm: Empirical results and comparisons with previous studies, Toxicological Sciences, 95:23-36.
  54. Jonsson F, Jonsson E.N., Bois F., Marshall S., 2007, The application of a Bayesian approach to the analysis of a complex, mechanistically based model, Journal of Biopharmaceutical Statistics, 17:65-92.
  55. Allen, B.C., Hack E.C., Clewell H.J., 2007,
    "Use of Markov chain Monte Carlo analysis with a physiologically-based pharmacokinetic model of methylmercury to estimate exposures in u.s. women of childbearing age".
    Risk Analysis, 27:947-959.
  56. Banks H.T., Ma Y., Potter, L.K., 2005,
    "A Simulation-based comparison between parametric and nonparametric estimation methods in PBPK Models",
    Journal of Inverse and Ill-posed Problems, 13:1•¡¹26.
  57. Bernillon P., Bois F., 2000,
    "Statistical issues in toxicokinetic modeling: A Bayesian perspective",
    Environmental Health Perspectives, 108(suppl.5):883-893.
  58. Bois F., 1999,
    "Analysis of PBPK models for risk characterization."
    Annals of the New York Academy of Sciences 895: 317-337.
  59. Bois F., 2000,
    "Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics."
    Environmental Health Perspectives 108 (suppl. 2): 307-316.
  60. Bois F., 2000,
    "Statistical analysis of Fisher et al. PBPK model of trichloroethylene kinetics."
    Environmental Health Perspectives 108 (suppl. 2): 275-282.
  61. Bois F., 2001,
    "Applications of population approaches in toxicology."
    Toxicology Letters 120:385-394.
  62. Bois F., 2003,
    "Toxicokinetic modelling of 2,3,7,8-tetrachloro-p-dioxin blood concentration after ingestion by women."
    Environnement, Risque et Sante 2:45-53.
  63. Bois F., Fahmy T., et al., 1997,
    "Dynamic modeling of bacteria in a pilot drinking water distribution system."
    Water Research 31:3146-3156.
  64. Bois F., Gelman A., et al., 1996,
    "Population toxicokinetics of tetrachloroethylene."
    Archives of Toxicology 70: 347-355.
  65. Bois F., Jackson E., et al., 1996,
    "Population toxicokinetics of benzene."
    Environmental Health Perspectives 104 (suppl. 6): 1405-1411.
  66. Bois F., Krowech G., et al., 1995,
    "Human interindividual variability in metabolism: the example of 4-aminobiphenyl."
    Risk Analysis 15: 205-213.
  67. Bois F., Maszle D., 1997,
    MCSim: A simulation program,
    Journal of Statistical Software, 2(9):
  68. Bois F., Paxman D., 1992,
    "An analysis of exposure rate effects for benzene using a physiologically based pharmacokinetic model."
    Regulatory Toxicology and Pharmacology 15: 122-136.
  69. Bois F., Smith M., et al., 1991,
    "Mechanisms of benzene carcinogenesis: application of a physiological model of benzene pharmacokinetics and metabolism."
    Toxicology Letters 56: 283-298.
  70. Bois F., Smith T., et al., 1999,
    "Optimal design for a study of butadiene toxicokinetics in humans."
    Toxicological Sciences 49: 213-224.
  71. Bois F., Woodruff T.J., et al., 1991,
    "Comparison of three physiologically-based pharmacokinetic models of benzene disposition."
    Toxicology and Applied Pharmacology 110: 79-88.
  72. Bois F., Zeise L., et al., 1990,
    "Precision and sensitivity analysis of pharmacokinetic models for cancer risk assessment: tetrachloroethylene in mice, rats and humans."
    Toxicology and Applied Pharmacology 102: 300-315.
  73. Brochot C., Bessoud B., et al., 2006,
    "Evaluation of antiangiogenic treatment effects on tumors microcirculation by Bayesian physiological pharmacokinetic modeling and magnetic resonance imaging."
    Magnetic Resonance Imaging, 24:1059-1067.
  74. Brochot C., Bois F., 2005,
    "Use of a chemical probe to increase safety for human volunteers in toxicokinetic studies".
    Risk Analysis 25:1559-1571.
  75. Brochot C., Marchand S., Couet W., Gelman A., Bois F., 2004,
    "Extension of the isobolographic approach to interactions studies between more than two drugs: Illustration with the convulsant interaction between pefloxacin, norfloxacin and theophylline in rats".
    Journal of Pharmaceutical Sciences, 93:553-562.
  76. Brochot C., Smith T.J., Bois F., 2007,
    "Development of a physiologically based toxicokinetic model for butadiene and four major metabolites in humans: Global sensitivity analysis for experimental design issues".
    Chemico-Biological Interactions, 167:168-183.
  77. Cancre N., Bois F., et al., 1999,
    "Screening blood donations for hepatitis C in central Africa: Analysis of a risk- and cost-based decision tree".
    Medical Decision Making, 19:296-306.
  78. Cancre N., Tall A., et al., 2000,
    "Bayesian analysis of an epidemiological model of P. falciparum malaria infection in Ndiop, Senegal". American Journal of Epidemiology, 152:760-770.
  79. Chiu W.A., Bois F., 2006,
    "Revisiting the population toxicokinetics of tetrachloroethylene".
    Archives of Toxicology, 80:386-386.
  80. Chiu W.A., Bois F., 2007,
    "An approximate method for population toxicokinetic analysis with aggregated data".
    Journal of Agricultural, Biological, and Environmental Statistics, 12:346-363.
  81. Chiu W.A., Micallef S., Monster A.C., Bois F., 2007,
    "Toxicokinetics of inhaled trichloroethylene and tetrachloroethylene in humans at 1 ppm: Empirical results and comparisons with previous studies".
    Toxicological Sciences, 95:23-36.
  82. Covington T.R., Gentry P.R., et al., 2007,
    "The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene",
    Regulatory Toxicology and Pharmacology, 47:1-18.
  83. David, R. M., H. J. Clewell, et al., 2006,
    "Revised assessment of cancer risk to dichloromethane II. Application of probabilistic methods to cancer risk determinations."
    Regulatory Toxicology and Pharmacology 45: 55-65.
  84. Diack C., Bois F., 2005,
    "Pharmacokinetic-pharmacodynamic models for categorical toxicity data,"
    Regulatory Toxicology and Pharmacology, 41:55-65.
  85. Eisenberg J.N, Seto E., et al, 1996,
    "Quantifying water pathogen risk in an epidemiological framework",
    Risk Analysis, 16:549-563.
  86. Franks S.J., Spendiff M.K., et al., 2006,
    "Physiologically based pharmacokinetic modelling of human exposure to 2-butoxyethanol",
    Toxicology Letters 162 (2006) 164•¡¹173.
  87. Gelman A., Bois F., Jiang J., 1996,
    "Physiological pharmacokinetic analysis using population modeling and informative prior distributions,"
    Journal of the American Statistical Association, 91:1400-1412.
  88. Hack E.C., 2006,
    "Bayesian analysis of physiologically based toxicokinetic and toxicodynamic models".
    Toxicology, 221:241-248.
  89. Hack E.C., Chiu W.A, et al., 2006,
    "Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites", Regulatory Toxicology and Pharmacology, 46:63-83.
  90. Johanson G., Jonsson F., Bois F., 1999,
    "Development of new technique for risk assessment using physiologically based toxicokinetic models",
    American Journal of Industrial Medecine, Suppl. 1:101-103.
  91. Jonsson F, Jonsson E.N., Bois F., Marshall S., 2007, The application of a Bayesian approach to the analysis of a complex, mechanistically based model, Journal of Biopharmaceutical Statistics, 17:65-92.
  92. Jonsson F., Bois F., Johanson G., 2001, Assessing the reliability of PBPK models using data from methyl chloride-exposed, non-conjugating human subjects, Archives of Toxicology, 75:189-199.
  93. Jonsson F., Bois F., Johanson G., 2001, Physiologically based pharmacokinetic modeling of inhalation exposure of humans to dichloromethane during moderate to heavy exercise, Toxicological Sciences, 59:209-218.
  94. Jonsson, F. and G. Johanson, 2003,
    "The Bayesian population approach to physiological toxicokinetic-toxicodynamic models - An example using the MCSim software."
    Toxicology Letters 138: 143-150.
  95. Liao K.H., Tan Y.-M., et al.,2007,
    "Bayesian estimation of pharmacokinetic and pharmacodynamic parameters in a mode-of-action-based cancer risk assessment for chloroform",
    Risk Analysis, 27:1535-1551.
  96. Lin H.I., Berzins D.W., et al., 2004,
    "A Bayesian approach to parameter estimation for a crayfish (procambarus spp.) bioaccumulation model".
    Environmental Toxicology and Chemistry: Vol. 23, No. 9 pp. 2259•¡¹2266.
  97. Loizou G., Spendiff M., 2005,
    "A human PBPK model for ethanol describing inhibition of gastric motility",
    Journal of Molecular Histology, 35:687-696.
  98. Lyons M.A., Yang R.S.H, 2008,
    "Computational toxicology of chloroform: reverse dosimetry using Bayesian inference, Markov chain Monte Carlo simulation, and human biomonitoring data",
    Environmental Health Perspectives, 116:1040•¡¹1046.
  99. Marino, D. J., H. Clewell, et al., 2006,
    "Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice".
    Regulatory Toxicology and Pharmacology 45: 44-54.
  100. Mezzetti M., Ibrahim J.G., et al., 2003,
    "A Bayesian compartmental model for the evaluation of 1,3-butadiene metabolism".
    Journal of the Royal Statistical Society, Series C, 52:291-305.
  101. Micallef S., Amzal B., Bach V., Chardon K., Tourneux P., Bois F., 2007, Sequential updating of a new dynamic pharmacokinetic model for caffeine in premature neonates, Clinical Pharmacokinetics, 46:59-74.
  102. Micallef, S., Bois F., 2004, [Application of physiological models to toxicokinetic data analysis], Journal de la Societe Française de Statistique, 145:15-32.
  103. Micallef, S., Brochot, C., Bois F., 2005, [Bayesian statistical analysis of toxicokinetic data], Environnement, Risque et Sante, 4:21-34.
  104. Nong, A., Y. M. Tan, et al., 2008,
    "Bayesian calibration of a physiologically based pharmacokinetic/pharmacodynamic model of carbaryl cholinesterase inhibition."
    Journal of Toxicology and Environmental Health - Part A - Current Issues 71(20): 1363-1381.
  105. Smith T., Bois F., Lin Y.-S., Brochot C., Micallef S., Kim D., Kelsey K.T., 2008, Quantifying heterogeneity in exposure-risk relationships using exhaled breath biomarkers for 1,3-butadiene exposures, Journal of Breath Research, 2:037018 (10 p.)
  106. Smith T., Lin Y.-S., Mezzetti L., Bois F., Kelsey K., Ibrahim J., 2001, Genetic and dietary factors affecting human metabolism of 1,3-butadiene, Chemico-Biological Interactions, 135-136, special issue):407-428.
  107. Spear R., Bois F., 1994, Parameter variability and the interpretation of physiologically based pharmacokinetic modeling results, Environmental Health Perspectives, 102(suppl. 11):61-66.
  108. Spear R., Bois F., et al., 1991,
    "Modeling benzene pharmacokinetics: Calibration and parametric sensitivity across three sets of animal data",
    Risk Analysis, 11:641-654.
  109. Verotta D., 2005,
    "Models and estimation methods for clinical HIV-1 data",
    Journal of Computational and Applied Mathematics, 184:275-300.
  110. Watanabe K., Bois F., 1996, Interspecies extrapolation of physiological pharmacokinetic parameter distributions, Risk Analysis, 16:741-754.
  111. Watanabe K.H., Bois F., et al., 1994,
    "Benzene toxicokinetics in humans: Bone marrow exposure to metabolites",
    Occupational and Environmental Medicine, 51:414-420.
  112. Watanabe K.H., Lin H.-I., 2005,
    "Bayesian estimation of kinetic rate constants in a food-web model of polycyclic aromatic hydrocarbon bioaccumulation",
    Ecological Modelling 181:229•¡¹246.
  113. Woodruff T., Bois F., et al., 1992,
    "Structure and parametrization of toxicokinetic models: Their impact on model predictions",
    Risk Analysis, 12:189-201.
  114. Woodruff T.J., Bois F., 1993,
    "Optimization issues in physiological toxicokinetic modeling: A case study with benzene",
    Toxicology Letters, 69:181-196.
  115. Yokley K. Tran H.T., et al., 2006
    "Physiologically-based pharmacokinetic modeling of benzene in humans: A Bayesian approach",
    Risk analysis, 26:925-943.